EventsThe 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics
Published
This submission belongs to the session S11. Formulation, Drug Delivery and Controlled Release of the event The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics
Published date
29 Oct, 2025
Academic Editor
author-avatarLídia Gonçalves
Citation
Ravi Maharjan, Seong Hoon Jeong, Next-Gen vaccine analytics: Computational optimization of lipid nanoparticle mRNA delivery systems using machine learning, in Proceedings of The 1st International Electronic Conference on Medicinal Chemistry and Pharmaceutics, 1 November–30 November 2025, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Next-Gen vaccine analytics: Computational optimization of lipid nanoparticle mRNA delivery systems using machine learning

image
Seong Hoon Jeong 1
1. Laboratory of Biopharmaceutics, College of Pharmacy, Yonsei University, Songdo, Incheon, 21983, Republic of Korea, South Korea
Abstract

This study presents a machine learning-driven framework to optimize critical quality attributes (CQAs) of mRNA-lipid nanoparticle (LNP) vaccines, addressing challenges in microfluidic manufacturing process efficiency and formulation stability. mRNA-LNP formulations (n = 24) were developed to evaluate the interplay of material attributes (ionizable lipids, phospholipids, PEGylated lipids), process parameters (flow rate ratio: 3–5; total flow rate: 12–20 mL/min), and lipid ratios (ionizable-to-cholesterol: 1.08–1.33; phospholipid-to-PEG: 3.76–6.67; N/P: 6–10) using I-optimal design of experiments (DOE). Key outcomes—including particle size (PS), polydispersity index (PDI), encapsulation efficiency (EE), and thermal stability—were analyzed using XGBoost/Bayesian optimization for microfluidic condition tuning (accuracy >94%) and a self-validated ensemble model (SVEM) for lipid mixture prediction (accuracy >97%). Results demonstrated that ionizable lipid selection significantly influenced LNP size: formulations with DOTAP achieved larger nanoparticles (94–96 nm) with high EE (95.5%), while MC3 produced smaller LNPs (51–57 nm) with reduced EE (79–85%). SVEM outperformed traditional models, with predicted PS (95–97 nm) closely matching experimental outcomes (94–96 nm). Furthermore, dual optimization of lipid ratios and process parameters enabled 96.6% encapsulated mRNA recovery and stabilized thermal profiles (heat trend cycle: −25°C to −10°C). Sucrose incorporation during lyophilization inhibited eutectic crystallization, maintaining PS within ±2 nm post-freezing. This work highlights the first application of SVEM for simultaneous lipid/process optimization in mRNA-LNP production, offering a quality-by-design (QbD) approach to accelerate scalable, continuous manufacturing. The framework’s >97% predictive accuracy supports rapid virtual screening of formulations, reducing experimental costs by 40%, and paves the way for robust, thermally stable vaccines tailored for diverse therapeutic applications.

Keywords
Machine learning
Microfluidic device
XGBoost/Bayesian optimization
Self-validated ensemble (SVEM) model
mRNA-LNP
Oral Presentation
QSAR Analysis of Curcumin Analogues as Potent LSD1 Inhibitors with Anticancer Potential
Injectable Biodegradable Implantable Matrices For Prolonged Anti-VEGF Delivery: Toward Minimally Invasive Retinal Treatments